218 related articles for article (PubMed ID: 30677777)
21. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
22. Altered balance between thyrotropin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries.
Le Dafniet M; Blumberg-Tick J; Gozlan H; Barret A; Joubert Bression D; Peillon F
J Clin Endocrinol Metab; 1989 Aug; 69(2):267-71. PubMed ID: 2502552
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
24. mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA; Abeledo-Machado A; Perez PA; Faraoni EY; De Fino F; Rulli SB; Ferraris J; Pisera D; Gutierrez S; Thomas P; Díaz-Torga G
Endocr Relat Cancer; 2019 May; 26(5):497-510. PubMed ID: 30856609
[TBL] [Abstract][Full Text] [Related]
25. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
26. Unusual clinical presentations of giant prolactinomas.
Grozinsky-Glasberg S; Shimon I
Pituitary; 2011 Dec; 14(4):340-4. PubMed ID: 19104942
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile?
Niculescu DA; Gheorghiu ML; Poiana C
Eur J Endocrinol; 2023 Apr; 188(4):R88-R97. PubMed ID: 36975104
[TBL] [Abstract][Full Text] [Related]
28. Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
Ferraris J
Front Endocrinol (Lausanne); 2022; 13():1057749. PubMed ID: 36714572
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor β1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study).
Elenkova A; Atanassova I; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
Eur J Endocrinol; 2013 Sep; 169(3):299-306. PubMed ID: 23801826
[TBL] [Abstract][Full Text] [Related]
30. The treatment of aggressive prolactinomas with everolimus.
Lin AL; Geer EB; Lala N; Page-Wilson G; Magge R; Young RJ; Tabar V
Pituitary; 2023 Aug; 26(4):474-481. PubMed ID: 37428396
[TBL] [Abstract][Full Text] [Related]
31. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
33. [Aggressive and resistant-to-treatment pituitary tumors].
Cuny T; Chanson P
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
[TBL] [Abstract][Full Text] [Related]
34. Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
Missale C; Boroni F; Losa M; Giovanelli M; Zanellato A; Dal Toso R; Balsari A; Spano P
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):7961-5. PubMed ID: 8367448
[TBL] [Abstract][Full Text] [Related]
35. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
36. Management of prolactinomas during pregnancy.
Witek P; Zieliński G
Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
[TBL] [Abstract][Full Text] [Related]
37. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.
Principe M; Chanal M; Karam V; Wierinckx A; Mikaélian I; Gadet R; Auger C; Raverot V; Jouanneau E; Vasiljevic A; Hennino A; Raverot G; Bertolino P
Endocr Relat Cancer; 2018 Sep; 25(9):795-806. PubMed ID: 30012586
[TBL] [Abstract][Full Text] [Related]
38. Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature.
Sari R; Altinoz MA; Ozlu EBK; Sav A; Danyeli AE; Baskan O; Er O; Elmaci I
Horm Metab Res; 2021 Jul; 53(7):413-424. PubMed ID: 34282593
[TBL] [Abstract][Full Text] [Related]
39. Prolactinomas in children and adolescents--consequences in adult life.
Duntas LH
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1227-32; discussion 1261-2. PubMed ID: 11964017
[TBL] [Abstract][Full Text] [Related]
40. Identification of somatotrophs, mammosomatotrophs, and mammotrophs by sandwich cell immunoblot assay in GH-secreting adenomas and prolactinomas: correlations between the proportions of hormone secreting cells and tumor size.
Kojima Y; Suzuki S; Yamamura K; Kawasaki T; Yamamoto I
Endocr J; 2000 Apr; 47(2):143-55. PubMed ID: 10943738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]